Skip to main content

Yuflyma News

Celltrion's Yuflyma (adalimumab-aaty) Receives FDA Interchangeability Designation for All Approved Dosage Forms and Strengths

INCHEON, South Korea, May 23, 2025 /PRNewswire/ – Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for Yu...

Data Suggests TNF Inhibitors Help Prevent Serious Complications in Children with Crohn's Disease

FRIDAY, Dec. 27, 2024 A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn’s disease. A new study published recently in the journal Gut shows c...

FDA Approves Yuflyma (adalimumab-aaty), a Biosimilar to Humira

JERSEY CITY, N.J.--(BUSINESS WIRE) May 24, 2023 --Celltrion USA today announced that the U.S. Food and Drug Administration (FDA) has approved Yuflyma® (adalimumab-aaty), a high-concentration ...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Ankylosing Spondylitis, Crohn's Disease - Maintenance, Crohn's Disease, Crohn's Disease - Acute, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis

Yuflyma patient information at Drugs.com